BRCA1,2 Screen®

BRCA1,2 Screen®

It may reveal a high risk of breast cancer

The BRCA1,2,Screen® genetic analysis examines the 34 most common mutations in the BRCA1 and BRCA2 genes which cause breast and ovarian cancer in women and increase the risk of prostate cancer in men. These genes are inherited independently of gender, so prevention is absolutely key across the population. This test is recommended for basic prevention, it is not a substitute for a complete BRCA1,2 gene test.

BRCA1,2 Screen
3 000 Kč


Within 15 working days after receipt of your sample.

More info


By oral swab or blood collection.

More info


An overview of your most frequently asked questions and our answers.

More info

In which situations it is appropriate to take the test


The BRCA1,2 Screen® genetic analysis is not covered by public health insurance. In the case of the indications listed in the following points, public health insurance covers a comprehensive genetic examination Inherited breast and ovarian cancer syndrome. 

    Indications for breast and ovarian cancer testing: 

    Sporadic forms: 

    • Ovarian cancer, fallopian tube cancer and primary peritoneal cancer regardless of age.
    • TNBC or medullary breast cancer under 60 years of age. 
    • Unilateral breast cancer in a woman under 45 years of age (under 50 years if there is no known family history).  
    • Separate primary breast cancers, first by age 50 or both by age 60 (bilateral or ipsilateral, synchronous or metachronous).
    • Synchronous breast and pancreatic cancer at any age.
    • Men with breast cancer at any age. 

    Familial occurrence: 

    • Family history of ovarian/fallopian tube/peritoneal carcinomas. 
    • At least three relatives with breast cancer at any age. 
    • Two relatives: 2 female relatives with breast cancer, at least one under 50 years of age, or both under 60 years of age.
    • A patient with breast cancer of any age with a direct relative with ovarian cancer, TNBC/medullary breast cancer, pancreatic cancer, male breast cancer, high-grade or primary metastatic pancreatic cancer. 

    Testing indications for prostate cancer: 

    • Incidence of ≥ 2 cases of prostate cancer in personal or family history, with at least one at age ≤ 55 years.
    • ≥ 3 cases of prostate cancer in close relatives, death due to prostate cancer. 
    • Prostate cancer (Gleason score ≥ 7) or primary metastatic prostate cancer and ≥ 1 case of breast cancer, ovarian cancer, endometrial cancer, bowel or stomach cancer, renal cell carcinoma, malignant melanoma, pancreatic cancer, bladder cancer, gallbladder cancer. 

    If you have a personal and/or family history of other cancers (colon or small bowel cancer, uterine cancer, kidney cancer, etc.), genetic analysis may also be covered by public health insurance after a risk assessment by a clinical geneticist.

    Schedule a genetic consultation.

    If you meet any of these indications, please contact us at
    800 390 390



    Inherited breast and ovarian cancer is caused by a congenital mutation in the BRCA1 or BRCA2 gene. Women with mutations in these genes have a risk of developing breast cancer of up to 87%. These mutations account for 63.6 % of the most common BRCA1 mutations detected and 54.2 % of the most common BRCA2 mutations detected. The risk increases with age, most often affecting women between the ages of 50 and 60. In the case of hereditary disposition, however, it is much earlier, already around the age of 30. Mutations in BRCA genes are associated with a higher risk of prostate cancer in men. 

    The number of people with a mutation in the BRCA1 or BRCA2 gene in the European population is 0.51% (1:195), of which those with a BRCA1 mutation are 0.21% (1:480) and those with a BRCA2 mutation are 0.31% (1:327), regardless of gender. The test is therefore suitable for both men and women as a preventive measure, as mutations in these genes not only cause breast and ovarian cancer, but also other cancers such as colon, pancreatic, biliary, stomach and skin cancer. Mutations in these genes are transmitted in 50% of cases regardless of gender.

    The BRCA1,2 Screen® genetic analysis detects the presence of the 21 most common mutations of the BRCA1 gene and the 13 most common mutations of the BRCA2 gene which occur in the Czech/European population and cause the risk of breast and ovarian cancer in women and prostate cancer in men. If a mutation is detected in a positively tested healthy person, appropriate preventive care is recommended for early diagnosis of possible cancer. 

    BRCA1,2 - the screen tests 34 mutations in BRCA1,2 genes, which are the most common in the Czech population: mutations c.181T>G, c.213-12A>G, c.5266dupC, c.68 _69del2, c.1687C>T, c.1881_1884del4, c.1938_1947del10, c.1953_1956del4, c.1961delA, c.2068delA, c.2411_2412del2, c.2488_2497dupAAGTATCCAT, c.3018_3021del4, c.3642_3643del2, c.3700 _3704del5, c.3756_3759del4, c.4065_4068del4, BRCA1:c.2263G>, BRCA1:c.1600C>T, BRCA1:c.5096G>A, BRCA1:c.5251C>T in BRCA1 gene and mutations c.8537_8538del2, c.658_659del2, c.3847 _3848del2, c.5645C>A, c.7913_7917del5, c.9403delC, c.9435_9436del2, c.1813dupA, c.2808_2811delACAA, c.3075_3076delinsTT, c.8042_8043delCA, c.8755-1G>A, c.9371A>T in the BRCA2 gene.

    You will receive the result within 30 working days.


    After ordering the test, you will receive an email with detailed information. A DNA sample is most often obtained through an oral swab or blood sample. You can perform the oral swab yourself in the comfort of your own home using a collection kit which will be sent to you by mail together with instructions and other documents. You can have your blood drawn at your local physician's office or at our outpatient clinic. The result of the analysis will be sent to you by e-mail or by post as agreed. In the case of a positive result, we recommend an appointment for a genetic consultation. 

    Frequently Asked Questions

    The time required for the laboratory examination (sample analysis) and the delivery date of the result vary according to the type and complexity of the examination. Usually it is in the order of weeks, for complex tests up to several months. The delivery date of the result is indicated in the details of each test on our website. In urgent situations, e.g. for a woman with a newly diagnosed breast or ovarian tumour before surgery, the oncopanel cancer test is performed in STATIM mode and the result is available within 3-4 weeks, whereas in normal mode it takes up to 6 months.
    Health insurance always covers genetic consultations recommended by the attending physician (usually a general practitioner, paediatrician, oncologist, gynaecologist or other specialist). During the consultation, a clinical geneticist will assess whether the indication criteria for testing for the predisposition genes are met; if so, the entire genetic test, including laboratory analysis of the sample and subsequent consultation with the geneticist/doctor, is covered by health insurance. If the criteria for the genetic testing are not met, the patient can pay for the selected/recommended test as a self-payment.
    After making an appointment, you will come to our office where you will first fill out a personal and family history questionnaire, or you can download it from here on our website and fill it out in advance, in the comfort of your own home. Remember to bring it with you afterwards. This is followed by a consultation with a doctor who will compile your three-generation family tree and decide on the indication for laboratory genetic testing. We also recommend that you bring medical reports from recent important examinations.
    Recommendation - a referral from the doctor who recommended the genetic consultation. Alternatively, a completed genetic family and personal history questionnaire, which can be downloaded here. However, the questionnaire can also be completed after you arrive at our office. Medical reports from previous examinations related to the requested genetic test. It is not necessary to be fasting for the genetic examination, so you can easily make an appointment in the afternoon.
    It has been reported that approximately 5-10% of cancers are caused by inborn changes in certain genes. One of the main goals of predictive genetic testing is the early identification of people at risk. If risk predispositions (gene mutations) are detected, preventive follow-up at specialised centres is recommended, where possible cancers are detected early and the chances of successful treatment are increased. In the case of high-risk mutations, preventive surgery may be recommended to make the risk of cancer in a given organ virtually impossible (for example, removal of the breast glands or removal of the uterus and ovary in BRCA1 or BRCA2 mutation carriers).
    If your first-degree relative (parents, siblings, children) develops colon cancer before the age of 45, your risk of developing this cancer is 5 times higher. If you have three first-degree relatives, your risk can be as high as 50%. In families with a history of recurrent bowel cancer or with a history of bowel cancer at a young age, it could be hereditary cancer syndrome (Lynch syndrome). In such cases, genetic consultation is recommended.

    Do you have a question or don't know which test to choose?

    Call us at 800 390 390 or contact us and we'll be happy to help.